NEW
YORK, July 21, 2022 /PRNewswire/ --
Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage
biopharmaceutical company developing regenerative therapeutics for
neurodegenerative disorders, today announced that it will hold a
corporate update conference call for investors. The call will
take place on Tuesday, July
26th at 4:30pm ET
and will be hosted by the Company's Chief Executive Officer, Dr.
Alan Tuchman, and its President and
Chief Science Officer, Dr. Daniel
Alkon. Drs. Tuchman and Alkon will also take live Q&A
following their prepared remarks.
The U.S. toll free dial-in for the conference call is (877)
407-8293, and the international dial-in number is 1-(201)
689-8349.
Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the anticipated initiation of a clinical trial to treat
Multiple Sclerosis with bryostatin and continued development
of use of Bryostatin-1 for Alzheimer's disease, Fragile X and other
cognitive diseases. Such forward-looking statements are subject to
risks and uncertainties and other influences, many of which the
Company has no control over. There can be no assurance that the
clinical program for Bryostatin-1 will be successful in
demonstrating safety and/or efficacy, that we will not encounter
problems or delays in clinical development, or that Bryostatin-1
will ever receive regulatory approval or be successfully
commercialized. Actual results and the timing of certain events and
circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Additional factors that may influence or cause
actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time
associated with drug development and related insufficient cash
flows and resulting illiquidity, the Company's patent portfolio,
the Company's inability to expand its business, significant
government regulation of pharmaceuticals and the healthcare
industry, lack of product diversification, availability of the
Company's raw materials, existing or increased competition, stock
volatility and illiquidity, and the Company's failure to implement
its business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the Securities and Exchange Commission. The Company does not
undertake to update these forward-looking statements.
Contact information:
Investors and Media
800-811-5591
ir@synaptogen.com
Robert Weinstein
Chief Financial Officer
Synaptogenix, Inc.
rweinstein@synaptogen.com
View original
content:https://www.prnewswire.com/news-releases/synaptogenix-announces-corporate-update-conference-call-301591017.html
SOURCE Synaptogenix, Inc.